Javascript must be enabled to continue!
Morphological and functional changes in the macular area in diabetic macular edema after a single intravitreal injection of aflibercept
View through CrossRef
AIM: To evaluate the changes in macular morphology and function after a single intravitreal injection of aflibercept in diabetic macular edema (DME) using optical coherence tomography angiography (OCTA) and MP-3 microperimetry.
METHODS: Twenty-eight patients (42 eyes) diagnosed with DME were treated with intravitreal injection of aflibercept. The changes in best corrected visual acuity (BCVA), central retinal thickness (CRT), foveal avascular zone (FAZ) area, vessel density of superficial retinal capillary plexus (SVD), vessel density of deep retinal capillary plexus (DVD), mean light sensitivity (MLS), 2° fixation rate (P1), 4° fixation rate (P2), and other indicators 1mo after treatment were compared; of these, BCVA was converted into logarithm of the minimum angle of resolution (logMAR), and the correlation among the factors was analyzed.
RESULTS: After treatment, logMAR BCVA was 0.47±0.24, which was significantly better than that before treatment (0.63±0.28, P<0.001). The CRT was 359.21±107.87 μm after treatment, which was significantly lower than before treatment (474.10±138.20 μm, P<0.001). The FAZ area, SVD, and DVD were not significantly changed after treatment compared with the baseline. MLS was 22.16±4.20 dB after treatment, which was significantly higher than before treatment (19.63±4.23 dB, P<0.001). P2 significantly increased after treatment than before treatment (P=0.007). P1 had no significant change after treatment than before treatment (P=0.086).
CONCLUSION: A single intravitreal injection of aflibercept effectively reduces macular edema and improves retinal sensitivity, fixation stability, and visual acuity, possibly without causing significant changes in the retinal vascular condition in a short time.
Press of International Journal of Ophthalmology (IJO Press)
Title: Morphological and functional changes in the macular area in diabetic macular edema after a single intravitreal injection of aflibercept
Description:
AIM: To evaluate the changes in macular morphology and function after a single intravitreal injection of aflibercept in diabetic macular edema (DME) using optical coherence tomography angiography (OCTA) and MP-3 microperimetry.
METHODS: Twenty-eight patients (42 eyes) diagnosed with DME were treated with intravitreal injection of aflibercept.
The changes in best corrected visual acuity (BCVA), central retinal thickness (CRT), foveal avascular zone (FAZ) area, vessel density of superficial retinal capillary plexus (SVD), vessel density of deep retinal capillary plexus (DVD), mean light sensitivity (MLS), 2° fixation rate (P1), 4° fixation rate (P2), and other indicators 1mo after treatment were compared; of these, BCVA was converted into logarithm of the minimum angle of resolution (logMAR), and the correlation among the factors was analyzed.
RESULTS: After treatment, logMAR BCVA was 0.
47±0.
24, which was significantly better than that before treatment (0.
63±0.
28, P<0.
001).
The CRT was 359.
21±107.
87 μm after treatment, which was significantly lower than before treatment (474.
10±138.
20 μm, P<0.
001).
The FAZ area, SVD, and DVD were not significantly changed after treatment compared with the baseline.
MLS was 22.
16±4.
20 dB after treatment, which was significantly higher than before treatment (19.
63±4.
23 dB, P<0.
001).
P2 significantly increased after treatment than before treatment (P=0.
007).
P1 had no significant change after treatment than before treatment (P=0.
086).
CONCLUSION: A single intravitreal injection of aflibercept effectively reduces macular edema and improves retinal sensitivity, fixation stability, and visual acuity, possibly without causing significant changes in the retinal vascular condition in a short time.
Related Results
Aflibercept or ranibizumab for the treatment of diabetic macular edema; a retrospective study
Aflibercept or ranibizumab for the treatment of diabetic macular edema; a retrospective study
Diabetic macular edema (DME) is a significant cause of diabetic retinopathy and a major cause of vision loss. In this study, we aimed to evaluate and compare the efficacy of two in...
Aflibercept or ranibizumab for diabetic macular edema
Aflibercept or ranibizumab for diabetic macular edema
Background: Vascular endothelial growth factor (VEGF) is the primary substance involved in retinal barrier breach. VEGF overexpression may cause diabetic macular edema (DME). Laser...
Assessment of Mouse VEGF Neutralization by Ranibizumab and Aflibercept
Assessment of Mouse VEGF Neutralization by Ranibizumab and Aflibercept
Abstract
There are many articles using bevacizumab, ranibizumab, and aflibercept as effective anti-vascular endothelial growth factor (VEGF) drugs in mice. However, it has ...
ASSOCIATION BETWEEN THE DEGREE OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA
ASSOCIATION BETWEEN THE DEGREE OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA
INTRODUCTION: WHO estimates more than 150 million diabetes patients worldwide. One of the complications of diabetes is diabetic retinopathy which is recognized as the leading cause...
A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series
A combination of suprachoroidal injection of triamcinolone using a custom-made needle and intravitreal Ziv-aflibercept every eight weeks to manage naïve/denovo central DME: a single-center retrospective case series
Abstract
Background
Previous studies have shown promising effects of combining intravitreal bevacizumab and suprachoroidal injection of triamcinolon...
THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA
THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA
Purpose:
To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic eyes.
...
Intravitreal ziv-aflibercept for myopic macular neovascularization after pars plana vitrectomy and silicone oil tamponade: a case report
Intravitreal ziv-aflibercept for myopic macular neovascularization after pars plana vitrectomy and silicone oil tamponade: a case report
Introduction and importance:
Myopic macular neovascularization (mMNV) is a significant complication of pathological myopia, leading to vision impairment. The pr...
Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration
Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration
AIM: To examine effects of switching intravitreal aflibercept to bevacizumab in neovascular age-related macular degeneration (nAMD).
METHODS: Data from patients treated for nAMD wi...

